TY - JOUR
TI - Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough
AU - Anastasilakis, A.D.
AU - Trovas, G.
AU - Balanika, A.
AU - Polyzos, S.A.
AU - Makras, P.
AU - Tournis, S.
JO - Journal of Clinical Densitometry
PY - 2021
VL - 24
TODO - 2
SP - 338-340
PB - HANLEY & BELFUS-ELSEVIER INC
SN - 1094-6950
TODO - 10.1016/j.jocd.2020.10.014
TODO - alendronic acid;  calcitonin;  carboxy terminal telopeptide;  collagen;  denosumab;  parathyroid hormone[1-34];  procollagen type 1 n terminal propeptide;  unclassified drug;  bone density conservation agent;  denosumab, adult;  aged;  Article;  backache;  bone density;  bone turnover;  case report;  clinical article;  disease exacerbation;  drug withdrawal;  female;  femoral neck;  fifth lumbar vertebra;  first lumbar vertebra;  fourth lumbar vertebra;  human;  lumbar spine;  middle aged;  nuclear magnetic resonance imaging;  osteopenia;  osteoporosis;  priority journal;  rebound associated vertebral fracture;  rebound associated vertebral fracture;  second lumbar vertebra;  spine fracture;  third lumbar vertebra;  thoracic spine;  thoracic vertebra;  bone remodeling;  diagnostic imaging;  postmenopause osteoporosis;  spine fracture;  treatment withdrawal, Bone Density;  Bone Density Conservation Agents;  Bone Remodeling;  Denosumab;  Female;  Humans;  Osteoporosis, Postmenopausal;  Spinal Fractures;  Withholding Treatment
TODO - Rebound-associated vertebral fractures (RAVFs) could occur in a minority of the patients who discontinue denosumab. In such patients, denosumab is often reinstituted to rapidly suppress bone turnover and avert the risk of additional fractures. Herein we report the cases of 2 patients who sustained RAVFs, and in whom resuming denosumab treatment did not avert the occurrence of new RAVFs a few months later, despite the suppression of bone turnover markers. It seems that denosumab reinstitution cannot completely eliminate the risk of new RAVFs and that the rebound of bone turnover may not be the sole mechanism to explain this phenomenon. © 2020 The International Society for Clinical Densitometry
ER -